Annals of Surgical Oncology, Vol 3, Issue 5 437-445, Copyright © 1996 by Society of Surgical Oncology

ARTICLES

Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model

R. C. Jones, M. Kelley, R. K. Gupta, J. A. Nizze, R. Yee, Z. Leopoldo, K. Qi, S. Stern and D. L. Morton
Roy E. Coats Research Laboratories, John Wayne Cancer Institute, Saint John's Hospital and Health Center, Santa Monica, California, USA.

BACKGROUND: Our polyvalent, allogeneic melanoma cell vaccine (MCV) induces immunoglobulin M (IgM) and immunoglobulin G (IgG) class antibodies to a 90-kDa glycoprotein melanoma-associated antigen (MAA). Additionally, MCV induces delayed-type hypersensitivity (DTH) responses that we previously correlated with survival. We hypothesized that early DTH responses to MCV and early humoral responses to the 90-kDa MAA expressed on MCV cells may be predictive of overall survival. We tested this hypothesis by monitoring immunologic profiles in 59 patients with melanoma who were receiving MCV after surgical resection of regional lymph node or soft-tissue metastases. METHODS: Blood was drawn before vaccine administration, biweekly for 6 weeks, and then monthly. DTH to MCV was recorded at 0, 2, 4, and 8 weeks of MCV therapy. Mean antibody titers during the first 6-week interval were calculated. Changes in DTH were calculated as the difference between peak and prevaccine values (delta DTH). RESULTS: At a median follow-up of 75.6 months (range 5-138), univariate analysis assigned prognostic significance to gender (p = 0.046), lymph node involvement (p = 0.024), delta DTH (p = 0.044), mean anti-90-kDa MAA IgG (p = 0.0009), and mean anti-90-kDa MAA IgM (p = 0.0014). In multifactorial analysis, only the three immunologic variables significantly impacted survival (p = 0.046, 0.0005, and 0.0053, respectively). A mathematical model based on delta DTH and mean anti-90-kDa MAA IgG and IgM titers closely approximated the observed individual and overall survival rates. CONCLUSIONS: The correlation between overall survival and initial humoral/cellular immune responses to MCV immunotherapy may be useful in selecting patients most likely to benefit from prolonged adjuvant immunotherapy.

This article has been cited by other articles:

				E. C. Hsueh, E. Famatiga, S. Shu, X. Ye, and D. L. Morton Peripheral Blood CD4+ T-Cell Response Before Postoperative Active Immunotherapy Correlates with Clinical Outcome in Metastatic Melanoma Ann. Surg. Oncol., October 1, 2004; 11(10): 892 - 899. [Abstract] [Full Text] [PDF]

				M. H. Chung, R. K. Gupta, E. Hsueh, R. Essner, W. Ye, R. Yee, and D. L. Morton Humoral Immune Response to a Therapeutic Polyvalent Cancer Vaccine After Complete Resection of Thick Primary Melanoma and Sentinel Lymphadenectomy J. Clin. Oncol., January 15, 2003; 21(2): 313 - 319. [Abstract] [Full Text] [PDF]

				E. C. Hsueh, R. Essner, L. J. Foshag, D. W. Ollila, G. Gammon, S. J. O'Day, P. D. Boasberg, S. L. Stern, X. Ye, and D. L. Morton Prolonged Survival After Complete Resection of Disseminated Melanoma and Active Immunotherapy With a Therapeutic Cancer Vaccine J. Clin. Oncol., December 1, 2002; 20(23): 4549 - 4554. [Abstract] [Full Text] [PDF]

				L. A. DiFronzo, R. K. Gupta, R. Essner, L. J. Foshag, S. J. O'Day, L. A. Wanek, S. L. Stern, and D. L. Morton Enhanced Humoral Immune Response Correlates With Improved Disease-Free and Overall Survival in American Joint Committee on Cancer Stage II Melanoma Patients Receiving Adjuvant Polyvalent Vaccine J. Clin. Oncol., August 1, 2002; 20(15): 3242 - 3248. [Abstract] [Full Text] [PDF]

				E. C. Hsueh, R. Essner, L. J. Foshag, W. Ye, and D. L. Morton Active Immunotherapy by Reinduction With a Polyvalent Allogeneic Cell Vaccine Correlates With Improved Survival in Recurrent Metastatic Melanoma Ann. Surg. Oncol., June 1, 2002; 9(5): 486 - 492. [Abstract] [Full Text] [PDF]

				M. H. Chung, R. K. Gupta, R. Essner, W. Ye, R. Yee, and D. L. Morton Serum TA90 Immune Complex Assay Can Predict Outcome After Resection of Thick (>=4 mm) Primary Melanoma and Sentinel Lymphadenectomy Ann. Surg. Oncol., March 1, 2002; 9(2): 120 - 126. [Abstract] [Full Text] [PDF]

				N. Habal, R. K. Gupta, A. J. Bilchik, R. Yee, Z. Leopoldo, W. Ye, R. M. Elashoff, and D. L. Morton CancerVax, An Allogeneic Tumor Cell Vaccine, Induces Specific Humoral and Cellular Immune Responses in Advanced Colon Cancer Ann. Surg. Oncol., June 1, 2001; 8(5): 389 - 401. [Abstract] [Full Text] [PDF]

				G. J. Tsioulias, R. K. Gupta, G. Tisman, E. C. Hsueh, R. Essner, L. A. Wanek, and D. L. Morton Serum TA90 Antigen-Antibody Complex as a Surrogate Marker for the Efficacy of a Polyvalent Allogeneic Whole-Cell Vaccine (CancerVax) in Melanoma Ann. Surg. Oncol., April 1, 2001; 8(3): 198 - 203. [Abstract] [Full Text] [PDF]

				M. C. Kelley, R. K. Gupta, E. C. Hsueh, R. Yee, S. Stern, and D. L. Morton Tumor-Associated Antigen TA90 Immune Complex Assay Predicts Recurrence and Survival After Surgical Treatment of Stage I-III Melanoma J. Clin. Oncol., February 15, 2001; 19(4): 1176 - 1182. [Abstract] [Full Text] [PDF]

				K. Pulford, B. Falini, A. H. Banham, D. Codrington, H. Roberton, C. Hatton, and D. Y. Mason Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma Blood, August 15, 2000; 96(4): 1605 - 1607. [Abstract] [Full Text] [PDF]

				M. L. Disis, K. Schiffman, T. A. Gooley, D. G. McNeel, K. Rinn, and K. L. Knutson Delayed-Type Hypersensitivity Response Is a Predictor of Peripheral Blood T-Cell Immunity after HER-2/neu Peptide Immunization Clin. Cancer Res., April 1, 2000; 6(4): 1347 - 1350. [Abstract] [Full Text]